In making some of these decisions about medication changes, there isn’t always a perfect answer, and people disagree, but I didn’t write this post to tell you that people disagree – hopefully most of you have figured that out by now! Anyway, here’s a brief overview of a recent scenario. A nursing home resident was started on Invokana (you’ll have to go back a few nights if you’re not too familiar with this med), who was also on a moderate dose of Lantus already – about 30-40 units daily if I recall right. The provider did feel that blood sugars were improved per a progress note a few months after initiation of Invokana. Now the A1C results maybe told a different story. They went from 8.2 to 8.1 three months later. So…would this justify the argument to continue a drug that’s in the ballpark of 300/mo? For me, I’d prefer to increase the Lantus (with no recent low blood sugars or signs of hypoglycermia) versus continuing with the Invokana. Obviously there a few more variables in the equation that I can’t recall, but I think this case demonstrates that there is more than “one way to skin a cat” as my gruff former high school science teacher would say!
Diabetes Case – Invokana

6 Comments
Submit a Comment Cancel reply
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Written By Eric Christianson
December 5, 2013
Looking for something?
Free PDF – Top 30 Medication Mistakes
Enjoy the blog? Over 6,000 healthcare professionals follow the blog, why aren't you? Subscribe now and get a free gift as well!
Recent Posts
Categories
Free PDF – Top 30 Medication Mistakes
Enjoy the blog? Over 6,000 healthcare professionals follow the blog, why aren't you? Subscribe now and get a free gift as well!
Buy on Amazon
Recent Posts
Archives
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
Categories
- BCACP Exam
- BCGP Exam
- BCMTMS Exam
- BCPS Exam
- Cardiovascular Case Studies
- Cardiovascular Medication and Disease State Clinical Pearls
- Career Advice for Pharmacy Students, Residents and New Pharmacists
- Clinical Guideline Updates For Pharmacists
- Clinical Pharmacy News and New Drug Updates
- Dermatology, ENT, Ophthalmology Case Studies
- Dermatology, ENT, Ophthalmology Medication and Disease State Clinical Pearls
- Drug Interaction Case Studies and Education For Pharmacists
- Educational Case Studies For Pharmacists
- Endocrine Case Studies
- Endocrine Medication and Disease State Clinical Pearls
- Free Clinical Practice Quizzes and Videos For Pharmacists
- Gastrointestinal Case Studies
- Gastrointestinal Medication and Disease State Clinical Pearls
- Hematology and Immunology Case Studies
- Hematology and Immunology Medication and Disease State Clinical Pearls
- Infectious Disease and Oncology Case Studies
- Infectious Disease and Oncology Medication and Disease State Clinical Pearls
- Long Term Care Consultant Pharmacist Education and Information
- Medication and Disease State Clinical Pearls For Pharmacists
- Medication Errors
- MPJE
- NAPLEX
- Neurology, Pain, and Musculoskeletal Case Studies
- Neurology, Pain, and Musculoskeletal Medication and Disease State Clinical Pearls
- Pediatrics Medication and Disease State Clinical Pearls
- Personal Stories From The Front Lines of Clinical Pharmacy
- Pharmacist Board Certification Information And Help
- Pharmacist Legislative Advocacy
- Pharmacogenomics and Pharmacokinetics Case Studies
- Pharmacogenomics and Pharmacokinetics Medication and Disease State Clinical Pearls
- Polypharmacy Cases And The Prescribing Cascade
- Psychiatry and Addiction Medication and Disease State Clinical Pearls
- Psychiatry and Addiction Medicine Case Studies
- Renal, Urology, and Electrolytes Case Studies
- Renal, Urology, and Electrolytes Medication and Disease State Clinical Pearls
- Respiratory Case Studies
- Respiratory Medication and Disease State Clinical Pearls
- Uncategorized
- Women’s and Men’s Health Case Studies
- Women’s and Men’s Health Medication and Disease State Clinical Pearls
- Writing Medication Recommendations For Pharmacists
Like cancer, each case of diabetes can be unique. Unfortunately, all of cases find the answer that diabetes is incurable, though some treatments are available to help control it.
Hopefully someday there is a cure for diabetes.
Just my 2 cents, Brandon
Thanks for the comment!
Would be interested to know what patients creatinine clearance is since apparently old enough to be in nursing home; med is less effective in CKD correct?
Invokana showed reductions in a1c in the 0.5-1% range, about even with Januvia. Furthermore, this reduction was additive. It also seems to reduce systolics by about 5mmHg and result in some weight loss (peeing at least 400 calories a day if I remember reading that correctly).
Waiting for long term CV safety data to come out in next year or so but unless that’s bad I think this will be a great second or third line drug. One downside is yeast infection and UTI. Would definitely monitor nursing home patient for this since UTIs seem to be more common and more troubling in that population anyway.
I’m being facetious when I say this seems like a case of, “it’s a new drug so let’s try it out for fun.” Not knowing the full story, I agree that the long-acting insulin could have been bumped up instead of piling on more drugs which brings more side effects and costs.
More details please. How was their kidney function? Kind of pointless to be on invokana if you only urinate once a day. Also what was the dose? 100Mg? If the kidney function was ok and they were on 100Mg then maybe it just needs to be increased.
Something seems off aa invokana normally gives 1 % normally woth proper use and counselling. While there is still room to increase the Lantus, many pts coming to oir endo clinic are over basal leading to higher a1c die to defensive eating due fears of hypos. To get from 8 to 7%, pt need meal coverage. From my experience of working with thousands of pts in the past 5 yrs in endo and as a CDE & BC-ADM, i see way too many pts over basal. There are couple papers one this for those of you who are interested.